Ophthalmic formulations

Details Ophthalmic formulations Ophthalmic formulations

2005-10-11

2005-10-11

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S054000

Reexamination Certificate

active

06953776

ABSTRACT:
A topical ophthalmic formulation in the form of an aqueous solution comprising a cyclosporin, hyaluronic acid or one of its salts, and polysorbate 80 is described.

REFERENCES:
patent: 5411952 (1995-05-01), Kaswan
patent: 5474979 (1995-12-01), Ding et al.
patent: 5739105 (1998-04-01), Kim et al.
patent: 5929048 (1999-07-01), Falk et al.
patent: 5951971 (1999-09-01), Kawashima et al.
patent: XP-002172972 (1991-09-01), None
patent: WO89/01772 (1989-03-01), None
patent: WO93/23010 (1993-11-01), None
patent: WO95/31211 (1995-11-01), None
Condon, Patrick et al., Double-blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy . . . , Br. J. of Ophthalmol 1999; 83:1121-1124.
Gowland, G., Fourfold Increase in Efficiency of Cyclosporin A when Combined With Hyaluronan: Evidence for Mode of Drug Transport and Targeting, Int. J. Immunotherapy XIV(1) 1-7 (1998).
Gowland, G. et al., Marked Enhanced Efficacy of Cyclosporin When Combined with Hyaluronic Acid, Clin. Drug. Invest 11(4) 245-250 1996.

Affiliated with

Also associated with

Rating

Ophthalmic formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ophthalmic formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3453500